HempFusion Wellness Inc. (CBD.U)

[Alexulf]

2 New Acquisitions! Sagely Naturals + Yesterdays!

[Alexulf]

Quarter 1 Report, Q 2 Coming Up Soon.

HempFusion Reports Q1, 2021 Financial Results
T.CBD.U | May 17, 2021
HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), an industry leader in full-spectrum cannabidiol (CBD) hemp extract wellness products and probiotics, today reported financial results for the first quarter ended March 31, 2021. All dollars are stated in US Dollars.

Q1-2021 Financial Highlights

Consolidated revenue increased 7.6% to $983,496 from $913,646 in Q4-2020
DTC sales increased 59.3% to $244,255 from $153,305 in Q4-2020
International sales increased to $75,994 from nil in Q4-2020
Gross profit of $280,205 or 28.5% of net revenue
Operating expenses were $6,306,703, an increase of 42.9% from $4,414,792 in Q1-2020, primarily attributed to IPO related expenses as well as marketing and digital related expenses
Strong cash position ending the quarter at $17,074,030
Q1-2021 Business Highlights


Completed a $17 million initial public offering (IPO) and commenced trading on the Toronto Stock Exchange (the “TSX”), becoming the first U.S.-based CBD and wellness products company to list directly on the TSX (senior board).
Became the No. 2 most recognized CBD brand in America according to Brightfield Group
As of the end of January 2021, NielsenIQ data rank HempFusion as the No. 1 in product sales and units sold in one of the largest food/drug/mass (“FDM”) retailers




E-Commerce success has shown a 62% increase in online traffic with a significant increase in conversion including a shift from 16.8% online sales in Q4-2020 as a percent of net revenue to 24.8% in Q1-2021


The Company launched the Probulin store on Amazon and early 2021 traction is encouraging. Consolidated net revenue for the three months ended March 31, 2021 increased 7.6% quarter-over-quarter to $983,496 versus $913,646 in Q4-2020. Direct to consumer (“DTC”) e-commerce net revenue increased 59.3% reflecting increased marketing efforts, a targeted DTC team and targeted digital promotions.


Not only did sales increase for both Probulin and HempFusion but the traffic has increased by 62% in Q1 2021 versus Q4 2020 with a conversion rate increase for Probulin of 2.1% to 3.2% and a current conversion rate for HempFusion of 3.4%. E-commerce accounted for 24.8% of net revenue in the first quarter of 2021 versus 16.8% for Q4, 2020. HempFusion's Probulin has seen 10% or greater month-over-month growth since launching on Amazon .


Officially launched Probulin on the world's largest e-commerce platform, Alibaba's Tmall Global, with HempFusion CBD following in a subsequent Q2 event!

Submitted dossier to the United Kingdom's Regulatory Food Safety Agency
"With nearly all international business paused due to COVID throughout 2020 and Q1 2021, and with slower than expected reopenings, the Company still achieved an incremental QoQ growth of 7.6% . Now, with vaccine rollouts taking place across the country, we are encouraged with reopening rates and excited that our sales, which currently take place in approximately 75% brick-and-mortar businesses, are beginning to reopen," commented Jason Mitchell, N.D., HempFusion's Co-Founder and Chief Executive Officer.

"We remain committed to developing new revenue channels and have entered additional countries including China, Ireland, and the United Kingdom, and we are excited with subsequent quarterly events in which new purchase orders were received, showing early signs of the return of international business. These international POs have the potential to drive millions in revenue. We are working feverishly to accelerate sales through organic channels and the continued pursuit of M&A opportunities; early indications have Q2 shaping up to be our best quarter yet," continued Dr. Mitchell.

Statements of Loss and Comprehensive Loss

The Below is from the Unaudited Condensed Interim Financial Statements for the Three Months Ended March 31, 2021 and 2020; Please Refer to the Complete Report, Including the Notes, Other Statements and Other Contents Therein.

Consolidated net revenue for the three months ended March 31, 2021 increased 7.6% quarter-over-quarter to $983,496 versus $913,646 in Q4-2020, and DTC e-commerce net sales increased 59.3% reflecting increased marketing efforts, a targeted DTC team, and targeted digital promotions. Site traffic increased by 62%, and conversion rates increased to 1.9%. DTC accounted for 24.8% of total revenue in the first quarter of 2021 versus 16.8% for Q4-2020.


International sales increased to $75,994 from nil showing a return to normal from Q4-2020, and early indication of future international orders accelerating and producing incremental quarterly gains. H empFusion maintains a leadership position in retailers across the United States, including the #1 in sales by dollar volume and SKUs in one of the top five largest FDM channel retailers.

Gross profit of $280,205 or 28.5% of net revenue is primarily attributed to improvement in inventory and supply chain management.

Operating expenses were $6,306,703, an increase of 42.9% from $4,414,792 in Q4-2020, primarily attributed to IPO related expenses, including D&O insurance and listing fees, as well as marketing and digital expenses.

Balance Sheet | Cash Position

The Below is from the Unaudited Condensed Interim Financial Statements for the Three Months Ended March 31, 2021 and 2020; Please Refer to the Complete Report, Including the Notes, Other Statements and Other Contents Therein.

The Company ended Q1-2021 with a strong cash position of $17,074,030 ensuring the capital requirements of the Company are met, with ample room for strategic M&A. The Company incurred $2,655,134 in general and administrative expenses and $3,651,569 in sales and marketing expenses.

“In 2019, HempFusion (combined with Probulin on a pro forma basis with respect to 2019) achieved net revenue of $4,627,544, followed by $3,823,638 in 2020. The impact COVID has had on our business is clear. We have adapted. It’s important to note we have strategically bolstered the Company’s online presence with the help of new channels such as Amazon for Probulin and Alibaba’s Tmall for both brands. Our efforts have resulted in early traction and success, as we continue to strengthen our foothold in the direct-to-consumer CBD market. This quarter showed a strong DTC sales increase of 59.3%. We expect this trend to continue as DTC now accounts for 24.8% of total revenue in the first quarter of 2021 versus 16.8% for Q4-2020,” commented Dr. Mitchell.

Conference Call

Management of the Company will host a conference call to discuss the Company's first quarter 2021 results at Monday, May 17, 2021 at 4:15 p.m., Eastern Time. To participate in the call, please dial 888-506-0062. For international callers, dial 973-528-0011. Use Participant Code: 795055. To join the webcast: https://www.webcaster4.com/Webcast/Page/2710/41342 .

A replay will be available from the Investor Relations section of HempFusion’s website at HempFusion.com/corporate-information .

ABOUT HEMPFUSION

HempFusion is a leading health and wellness CBD Company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .

Follow HempFusion on Twitter , Facebook and Instagram and Probulin on Twitter , Facebook and Instagram .









FacebookTwitterLinkedInCopy LinkMore

(0) (0)






Hempfusion Wellness Inc (CBDHF) or (CBD-U.TO) + Frankfurt (CBDHF / CBD-U.TO) Stock Research Links


CBDHF / CBD-U.TO Message Board

[Alexulf]

ARTICLE ON THE COMPANY

https://www.valuethemarkets.com/invest/hemp-fusion-wellness-hfw001-02/

[Alexulf]

CBD, Cannabidiol Market Anticipated To Grow At A Lucrative Rate Through 2027 As Consumer Demand Rapidly Increases


PALM BEACH, Fla., May 12, 2021 /PRNewswire/ -- Due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products. Cannabidiol derived from hemp is anticipated to witness rapid growth owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health.


Increasing consumer disposable income along with the legalization of medicinal cannabis is anticipated to have a positive impact on the demand for cannabidiol in the pharmaceutical sector. Oils, tinctures, concentrate, capsules, topical solutions such as slaves, lip balms, lotions, and edibles such as baked goods, coffee, chocolates, gums, and candies are some of the CBD products which are in high demand. According to reports from Grand View Research the global cannabidiol; market size is expected to reach USD 13.4 billion by 2028, and is expected to expand at a CAGR of 21.2% from 2021 to 2028.


The report said: "Increasing awareness about the health benefits of cannabidiol (CBD), changing consumer opinion, and attitude toward CBD products are some of the key factors driving the demand for these products. Furthermore, increasing demand for cannabidiol from various end-user industries such as food and beverage, personal care and cosmetics, and pharmaceuticals is expected to trigger market growth…" One of the coming giants can be; HempFusion Wellness Inc. (TSX:CBD-U.TO) (OTCQX:CBDHF)



The Grand View Research report continued with: "In 2020, the hemp segment accounted for the largest revenue share valued at USD 1.7 billion, owing to the rising awareness regarding the health benefits of products infused with cannabidiol derived from marijuana. On the other hand, hemp-derived CBD is expected to witness the fastest CAGR over the forecast period, owing to the increasing legalization of hemp in various countries. Increasing awareness of cannabidiol's therapeutic benefits has influenced a buyer to buy cannabidiol products, regardless of their cost. As these have a greater profit margin, commercial retailers are now focusing on selling cannabis-based products. Numerous health and wellness retailers are offering CBD-based products.

[Alexulf]

HempFusion CBD Review - Strong position in US CBD sector forecast to reach US$16 billion by 2025.

2

Industry-leading regulatory compliance could allow CBD product range to expand as the market opens up and regulation tightens.

3

Strong existing US retail and an extreme focus in increasing e-commerce position with large R&D pipeline

4

Planning to expand into enormous US Big Box Retail, Convenience, and Doctor/ practitioner channels as well as internationally.

5

Robust balance sheet and expert leadership team.

6

Recent market listings open firm up to investors hungry for CBD exposure.


The whole story; https://www.valuethemarkets.com/invest/hemp-f...hfw001-02/

[Alexulf]

RETAIL IS ALL-IN: LOOK OUT BELOW!

Wealth Research Group [e-mail] via gmail.mcsv.net
14:45 ( 8 hours ago)


Follow us on G+, Facebook, YouTube and Twitter.
View this email in your browser


Google Plus

Facebook

Twitter

YouTube

Website
Don't Fight The FED
For the past few days, I've been spending quality time in Wyoming at a ranch resort. Yesterday, while speaking with the guide at the aerial ropes course, I learned that Elon Musk, Jeff Bezos, Bruce Springsteen, and Tom Hanks, as well as Ivanka Trump, are all past visitors of this resort. NFL and NBA players also like to book their shooting and fishing vacations in this ranch.


While at the aerial ropes course, we had two levels of height, with one being 25ft and the other 40ft. When climbing to those levels, the sense of the ascent is noticeable. What's interesting about the course is that because of the equipment, the participants are 100% safe since falling just means one is caught between the earth and the sky, but no harm comes to him.


Yet, the fear does exist in the heart of both adults and children.


Some fears, I believe, are simply either innate or as close to engrained as they come. The guide that helped us through the various challenges had told me that the first time she climbed up there, she sobbed and cried, never trusting the gear and was emotionally traumatized by the sheer height and foreign experience of not having her feet on the ground.


By the tenth day of training, she completely had faith in the equipment and has never looked back.


In the aerial ropes course, the fear is mostly mental, since the likelihood of injury is nearly non-existent. As a beginner, you'll surely feel overwhelmed and outside of your element, so you must push through that and get to the point where you're comfortable with the adventure.


In the stock market, it is pretty much the same; the beginner will always feel like he has invested at the worst possible time and anything can cause uneasiness and discomfort.


The thing is that both on the ropes course and in the markets, one can take his time and gradually work his way up. I started at the 25ft level and then climbed to 40ft, eventually doing the zip line as well.


There's no need to panic and if you do – and it happens to everyone – keep in mind that buying an index fund has never lost anyone money over the long term.


America is growing through trials and tribulations, but it's kicking ass, nonetheless.


All of the political turmoil, with the divisiveness and the bad vibe, doesn't stop the economic machine from producing vast wealth.


When we were on that course, adults and children were climbing it together. I actually think that some kids are less fearful than adults, since they don't think about the height factor that much.


A lot of rich people, who own successful businesses, tend to invest like the few who just choose to watch and not participate.


All they did was take pictures, missing the exhilaration of knowing that they accomplished a special thing.


In order to grow mentally or to have more, financially speaking, you must either own your own business or invest in publicly-traded ones. Some even say that the Federal Reserve acts like the clips that link you to the ropes, so that no fall would be too hard.


I don't rest my hopes on that theory, but I still put the majority of my net worth in equities, because it works.


Best Regards,


Lior Gantz
President, WealthResearchGroup.com

[Alexulf]

HempFusion’s CBD strategy ahead of the competition in the CBD space

https://www.dropbox.com/s/bgd6ix3rj79aa02/HempFusion%20Corporate%20Presentation%20April.pdf?dl=0

[Alexulf]

HempFusion Inc; Investor Presentation - The https://www.dropbox.com/s/bgd6ix3rj79aa02/Hem...l.pdf?dl=0


VIDEO;

[fil]

HempFusion Wellness Announces Toxicology Results from Validcare’s Clinical Study on CBD Liver Safety
Tue March 23, 2021 9:20 AM|Business Wire|About: CBDHF

DENVER, Colo.--(BUSINESS WIRE)-- HempFusion Wellness Inc. (CBDHF) (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, is pleased to announce that Validcare, the organization coordinating the execution of what the Company believes to be the largest human observational, liver and human toxicology study to date, has released its initial findings from the industry sponsored, decentralized human safety study of hemp derived CBD products. The preliminary findings are validating and encouraging, and according to the study’s investigators, there was no evidence of liver toxicity in the 839 participants in the clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005376/en/

[CanadianInvestor33]

HempFusion announced today that it is entering China with Probulin Probiotics through Alibaba Group's Tmall Global, Reaching More Than 750 Million Potential New Consumers! This is big news for HempFusion.

Huge Revenue opportunities for HempFusion! Could see major gains on this stock!

https://www.businesswire.com/news/home/20210318005195/en/HempFusion-Wellness-Enters-China-with-Probulin-Probiotics-Through-Alibaba-Group%E2%80%99s-Tmall-Global-Reaching-More-Than-750-Million-Potential-New-Consumers

[BullishTrader 99]

Awesome news today, lets have a green day! Linked the article for all that are interested! Link to full article: https://ca.finance.yahoo.com/news/hempfusion-top-performing-topical-cbd-120500393.html

[BullishTrader 99]

Hempfusion will bounce back big time next week, great time to average down while you still can! BUY THE DIP!

[TheTrader12]

In my opinion HempFusion Wellness Inc. (TSX:CBD.U) is a leading player in the cannabidiol (CBD) market.

HempFusion recently announced that it would commence trading on the US OTC Market under the symbol, CBDHF. Following this development, we have seen an influx of interest in HempFusion from US investors and this is a trend that caught our attention. HempFusion already has over 4,000 retail investors, but with the company introducing its shares to the US markets we expect this number to grow rapidly.

One of the reasons I are excited about HempFusion is their ability to raise capital to fund key growth initiatives. Since inception, the health and wellness CBD company has raised more than $55 million. When compared to other CBD operators, HempFusion has been able to raise capital in a much easier and quicker way, and we find this to be a key aspect of the story.

Last week, GW Pharmaceuticals plc (GWPH) was acquired by Jazz Pharmaceuticals plc (JAZZ) for more than $7 billion. GW is a biotech cannabis company that is focused on developing plant based treatments for major indications. Through clinical trials, GW has been able to prove that CBD has a significant number of benefits and we believe that this, combined with the significant acquisition, has added a level of credibility to the CBD sector.

Although HempFusion is focused on a different aspect of the CBD market, we believe the acquisition of GW is a positive for the business and expect to see increased interest as a result. During the last year, several large CBD brands have filed for bankruptcy and the sector has become less saturated as a result.

I believe that HempFusion will prove to be a winner in the CBD sector and consider it to be one of three main brands in the space. Currently, the company is competing against Charlotte’s Web Holdings, Inc. (CWEB.TO) and cbdMD, Inc. (YCBD) and we are favorable on the long-term growth prospects that is associated with the business.

Over the next year, I expect HempFusion to report an increase in the number of stores that sell the brand and believe that the market is discounting the growth prospects that is associated with this. We believe HempFusion will benefit from owning a proprietary product line and are monitoring how the products continue to gain traction.

Another reason I am excited about HempFusion is the structure of the business. The company owns a diverse product line and sells a premium line of probiotic products. The product line, Probulin has served as a major revenue generator and we expect the company to use the cash flow from this vertical to grow the CBD business.

When you combine HempFusion’s ability to raise capital with the cash flow that the business is generating, I believe that you have a recipe for success and expect this formula to support organic growth in the near and long-term.

Another key pillar of our thesis on HempFusion is related to the strength of the management team. The company is led by a team that has diverse expertise and a proven track record of success in several highly regulated industries. I believe the strength of the management team is one of the most important aspects of the story and are favorable on the direction the business is heading.

One of the ways that HempFusion has been able to differentiate itself from other CBD operators is by focusing on the development of an organic product line. Last month, the company reported to have received an organic certification from the United States Department of Agriculture (USDA) for several of its CBD tinctures. This development makes HempFusion one of the first publicly traded CBD brands to receive the designation and we find this to of importance.

Currently, HempFusion’s family of brands are available through approximately 4,000 retailers in the United States and select international markets. The company has a diverse product portfolio that is comprised of 46 SKUs and we believe that our readers need to be aware of this opportunity.

At current levels, we believe that HempFusion has an attractive risk-reward profile and a compelling valuation. When compared to its peers, we believe the health and wellness CBD company is trading at a discount and see significant upside potential to current levels. As HempFusion continues to execute on its growth strategy, we expect the business to receive additional coverage from leading broker-dealers and believe that this will be a catalyst for growth.

Disclaimer: Please do you own research, this is not investment advice.

[BullishTrader 99]

Massive Upside Get in While You Still Can! - HempFusion has had some fantastick news recently, I believe this stock is poised to keep growing as they now offer electronic settlement, DTC eligibility will provide a larger platform to attract more investors and continue to bump up the volume! In addition, HempFusion is now the Exclusive Supplier for Clinical Trial at Mount Sinai Medical Hospital, Located in New York! Just huge news for this stock recently, I see some massive upside potential on this stock! Get in while you still can, as CBD.U is truly one of the last pure play CBD companies out there and you don't want to miss out on this one!

[TheTrader12]

Still a hidden GEM. People will be laughing when it is at $5.

Highly-Anticipated Regulation Changes In 2021 Could Revolutionize America’s CBD Sector!!!

[SmallCapIntel]

In a sea of red its been really nice seeing $CBDHF keep up like that have since IPO. Found this interview from their CCO on some of the market action we've been seeing:

[Troytex]

Hemp Fusion had the very best presentation feb 24-25 at Benzinga conference..very informative..no fluff or pump.Will plan to buy small stakes ASAP troy in Texas

[Ian345]

This bad boy is a good one

I just keep saying this as my position keeps going up steadily.

Love the products as well.

[fil]

It should also be noted that the company’s CEO has formulated over 300 dietary supplements and is an expert in the FDA process the many brands at market will face when the FDA gives guidance.

[fil]

While the FDA has not committed to a legal framework and there are regulatory uncertainties, this is the beginning of a very big market and HempFusion has positioned itself for when that headwind turns into a tailwind.

[fil]

To date HempFusion has launched 8 FDA Drug Listed OTC topicals.

[fil]

HempFusion’s FDA drug listed OTC topicals are a game-changer, providing the company with a significant industry differentiator that very few competitors have achieved.

[Ian345]

This is a good one

[ED25]

CBD.U $$$$

[Ian345]

Hempfusion starts trading today.

Can it be the next CWEB?

[Ian345]

CBD.U set to List on Jan. 6th